Background: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects. However, the use of CBDCA higherintensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.
Introduction
The advent of platinum-based chemotherapy represented a milestone in the treatment of several solid neoplasms, including those of the ovary, testis, head-and-neck, lung and brain. Of the platinum compounds, the most widely used is cisplatin (CDDP), which is clearly effective but, on the other hand, is severely neurotoxic on the sensory pathway, where it primarily damages the dorsal root ganglia (DRG) neurons [1] [2] [3] [4] [5] . CDDP neurotoxicity may be very severe and disabling, so in recent years several platinum-derived drugs have been evaluated to overcome the neurotoxicity of CDDP without reducing the anti-cancer effectiveness of the substance. Carboplatin (CBDCA) is the most successful product of this research and, in fact, is now widely used in clinical settings [6] . Although the neurotoxicity of CBDCA is markedly less than that of CDDP, it is not completely absent [7] [8] [9] . This fact is significant, since CBDCA is currently being associated with other neurotoxic drugs (i.e., taxoides) in clinical trials [9] and the possibility of cumulative neurotoxicity has not been completely ruled out. Moreover, it has recently been proposed that high-dose schedules of CBDCA increase the tumor response rate.
It seems, therefore, that an animal model would be helpful for more precisely estimating the type and severity of nervous system damage during CBDCA administration. In this study we chronically treated with two different schedules of CBDCA a series of adult rats and compared the neurophysiological, behavioral, morphological and analytical results against control rats.
Materials and methods
Twenty-four adult female Wistar rats (230-250 g at the beginning of the experiment) were used for the experiments, which were performed according to Italian and European Union laws concerning handling and treatment of experimental animals. The rats were divided into three groups of eight animals each and randomly assigned to receive i.p. administration of CBDCA at a dose of 10 mg/kg twice a week for nine times (group 1, total dose 90 mg/kg), CBDCA 15 mg/kg twice a week for nine times (group 2, total dose 135 mg/kg) or sterile saline (group 3). The drug was dissolved immediately before use in sterile saline (2 ml) which was also used to perform sham injections in controls. Weight was recorded before each injection and dose adjustment was performed accordingly. Animals were housed in individual plastic cages, fed with commercial rat cubes and water ad libitum and kept on a 12:12-hour dark-light cycle. Before the treatment and at the end of the study each animal underwent the tail-flick test for pain detection and determination of nerve conduction velocity (NCV) in the tail as previously described in detail [10] . At the end of the experiment all of the animals were sacrificed under deep anesthesia via intracardiac perfusion with 3% glutaraldehyde in 0.12 M PBS and subsequently processed for light and electron microscopy according to the standard methods of our laboratory [2] .
Light and electron microscopic morphological examinations were performed on sciatic and DRG specimens obtained from each animal. The morphometric determinations on 1 um-thick semi-thin DRG sections were performed with an automatic image analyzer TAS Plus (Leica GmbH) [2. 11] . In order to assess the tissue platinum concentration after treatment, DRG, sciatic nerve, liver, muscle and brain specimens were obtained from high-dose CBDCA-treated rats (group 2) and controls. Tissue platinum concentrations were determined in each animal on single samples of sciatic nerve, liver, kidney, muscle and brain and on pooled samples (n = 10) of DRG with inductivelycoupled mass spectroscopy (ICP-MS) [11] .
All of the behavioral, neurophysiological, morphological, morphometrical and analytical determinations were performed by examiners who were not aware of the treatment administered to the animals under investigation. Statistical evaluation of the results obtained in the comparisons between controls and CBDCA-treated rats and between the two different regimens of CBDCA treatment (to assess any dose dependency of the results) was performed using analysis of variance (ANOVA) followed as post test by the Tukey-Kramer test for multiple comparisons; significance was set at the P < 0.05 level.
Results

General toxicity
All of the rats completed the treatment period. CBDCAtreated rats had reduced weight gain during the treatment in comparison with controls (Figure la). Weight gain impairment was significant in group 2 (high CBDCA dose, P < 0.01) vs. controls (group 3) and it was dose-dependent. In fact, the increase in weight gain was not significantly reduced in the low-dose CBDCA group (group 1) vs. controls. During treatment, several rats in CBDCA groups 1 and 2 had moderately reduced motility which became evident after seven to eight injections. Piloerection, alopecia and constipation were occasionally observed in the groups of platinum-treated rats, and they were considered as non-specific signs of general toxicity.
Neurophysiological and behavioral determinations
NCV determinations in the tail was evidence of a significant impairment induced by both low-and high-dose CBDCA (mean NCV 33.5 m/sec ± SEM 1.0 in group 1, P < 0.001, 30.0 ± 2.0 in group 2, P < 0.001) in comparison with controls (43.8 ± 2.0). The difference between the results in group 1 and group 2 was not significant. Figure lb reports the data obtained before and after treatment in the three groups.
Evaluation of the results of the tail flick test obtained after treatment showed a dose-dependent impairment in pain perception: tail-flick test results increased after CDBCA (mean 5.61 sec ± 0.19 in group 1 and 6.48 ± 0.14 in group 2, P < 0.05 group 1 vs. group 2) administration in comparison with controls (4.58 ± 0.18). The statistical comparison demonstrated that the increase observed in all treated groups was significant (P < 0.01 in group 1 and P < 0.001 in group 2) when compared to control values. Figure lc reports the data obtained before and after treatment in the three groups. 
Morphological and morphometrical evaluations
At the light microscope, CBDCA treatments induced the changes in the DRG neurons which have already been described after CDDP administration [2, 10, 11] . Pathological changes were represented by an increased incidence of multinucleolated neurons and eccentric nucleoli ( Figure 2) . No evidence of cell death was observed. Satellite cells were of normal aspect. In the sciatic nerve no clear-cut alterations could be detected at the light microscope in CBDCA-treated rats, although rare fibers undergoing axonal degeneration were occasionally seen. At the electron microscope, nucleolar segregation was present in DRG neurons in both groups of CBDCAtreated rats. Focal clearing of the nucleoplasm was occasionally observed in platinum-treated rats. No cytoplasmatic changes were present in the animals. In both treated groups satellite cells showed the typical pathological changes previously observed in CDDP-intoxicated rats, represented principally by a reduction in size of the heterochromatin clumps located in the center of the nucleus and a thinning of the peripheral rim [2, 10, 11] . A slight widening of the space between them and the neuron plasmamembrane could also be observed on some occasions. In the peripheral nerves only initial signs of axonopathy, represented mostly by intra-and adaxonal accumulation of organelles and, more rarely, by wallerian-like changes affecting the largest myelinated fibers, were observed in all platinum-treated rats. No evidence of active or previous demyelination was seen. Unmyelinated fibers and Schwann cells were fairly normal.
Morphometric determinations performed on the DRG neurons demonstrated a significant reduction in the nucleolar area in CBDCA-treated rats in comparison with controls (10.5 ± 0.47, P < 0.01 in group 1,10.1 ± 0.46, P < 0.01 in group 2, controls 12.0 ± 0.32). No significant differences were observed between group 1 and group 2. Also nuclear area changes in high-dose CBDCA-treated rats (128.8 ± 5.4, P < 0.05) were significant when compared to controls (138.3 ± 4.6), while, in contrast, group 1 (low-dose CBDCA-treated rats) results were not significantly different (132.3 ± 4.7). Similarly, although the somatic area was reduced in both of the platinum-treated groups, only in group 2 CBDCA-treated rats (834.3 ± 43.6, P < 0.05) was the decrease significant vs. controls (961.9 ± 27.1), while in group 1 it was not significant (860.1 ± 37.7).
Analytical determinations
Tissue platinum concentrations were measured in group 2 (high-dose CBDCA) and compared with control rat tissues, where no platinum content was detectable in any of the cases. After CBDCA administration, platinum reached the highest concentrations in the kidney, but considerable amounts of platinum were also evident in DRG. The amounts of platinum in sciatic nerve, muscle and liver were lower than in DRG, while platinum concentration in the brain was detectable but extremely low. Table 1 reports the results of the analytical determinations in detail.
Discussion
One of the principal reasons for the clinical use of CBDCA rather than of CDDP in antineoplastic chemotherapy is that its neurotoxic effect is markedly reduced, while its anticancer activity remains high [6] . The present study, however, demonstrates that CBDCA may also be significantly neurotoxic when administered at high doses. This result is only apparently in disagreement with most of the clinical data reported thus far. A fact which needs to be taken into consideration is that the majority of the clinical studies which have reported no or only mild CBDCA neurotoxicity in the past were performed using drug doses which were generally lower than those which can be achieved nowadays, when the support of hematopoietic growth factors may reduce the hematological toxicity of CBDCA. Moreover, the current tendency is to use a combination chemotherapy [9] of CBDCA and taxoids (themselves neurotoxic), which is expected to increase the antineoplastic action, but may also enhance the risk that clinically-relevant neurotoxicity will ensue. We have previously described a well characterized model of CDDP neurotoxicity [2, 10, 11] which was used in this experiment as a 'positive' reference for the models of CDBCA neurotoxicity. The doses of CBDCA used in the experiment (five and 7.5-times higher than the established CDDP dose) were arbitrarily chosen in order to deliver chronically a relatively high, but non-lethal, dosage of the drug. No data concerning dose equivalence between CDDP and CBDCA in models similar to ours are available, so we extrapolated the dose of CBDCA to be administered from previous single-dose i.v. and i.p. studies in rats (see ref. [12] for review of the data). As a general reference, however, the single doses of CBDCA used in our models were on the same order of magnitude as those used in clinical practice in humans. A definite confirmation that the CBDCA schedules used were neurotoxic but tolerable by rats was the fact that all the treated animals survived until the end of the experiment, and that the general side effects induced by the treatment were never severe.
The overall evaluation of the behavioral, neurophysiological and pathological results indicated that the modifications induced by CBDCA are very similar in qualitative terms to those previously observed in our model of chronic CDDP treatment. Moreover, in CBDCA as well as in CDDP-treated animals, most of the changes showed a clear dose-dependency. In fact, the low-dose CBDCA regimen results are always less impressive and, sometimes, not significantly different from controls. It should be noted, however, that neurotoxicity was also present in the low-dose CBDCA group.
CBDCA-treated rats underwent a reduced weight gain in comparison to controls, as is commonly observed in similar experiments with toxic agents. Our neurophysiological and histological data, however, are very different from the results obtained by Cornblath and Brown [13] in their detailed report on Malnutrition' neuropathy and definitely rule out this possibility, pointing, on the contrary, to a specific effect of CBDCA. Moreover, the absence of a close link between impaired weight gain and reduced NCV in our experimental model is further indicated by the results obtained in the low-dose CBDCA-treated rats. In this group, in fact, weight gain is not significantly different from that of controls, while NCV is significantly reduced (P < 0.001) and axonopathic changes are present in the sciatic nerve.
After high-dose CBDCA treatment, the overall distribution of tissue platinum also closely resembled the one we previously reported after experimentally-induced CDDP intoxication [11, 14] , although the absolute values could not be compared because of the different analytical techniques used in the experiments. The highest platinum concentration was measured in the kidney (a result consistent with the well-known renal handling of CBDCA), a moderately high concentration was observed in the DRG, while lower concentrations in the sciatic nerve, muscle and liver, and an extremely low amount of platinum were detectable in the brain.
The marked similarities in the toxic damage induced by CDDP and CBDCA observed with all of the methods used to examine the animals and the tissue platinum distribution, suggest that the two drugs may have a common mechanism and site of action for their neurotoxicity (as well as for their anticancer action). However, no completely satisfying explanations of the mechanism at the basis of the onset of CDDP neurotoxicity are available at present, although it has long been studied extensively both in vitro and in vivo [15, 16] . The clear facts are that the DRG are the principal site of damage after CDDP administration and they represent the site where platinum concentration is highest in the nervous system. In the DRG, the most impressive changes are in the nucleolus of the primary sensory neurons, even if it is probable that platinum-containing drugs can be highly reactive also in the cytoplasm of DRG neurons and satellite cells with possible extensive binding with nucleophilic substances and proteins. Reduced protein synthesis in DRG neurons with derangement and impairment of axonal transport seem to be implicated in the onset of the secondary peripheral nerve damage after CDDP treatment [17] . Since the changes observed in our model are so similar, our data suggest that the hypothesis put forward to explain CDDP neurotoxicity may be extended also to CBDCA.
In conclusion, although when used at conventional doses in clinical prctice CBDCA is practically nonneurotoxic, our study confirms that CBDCA is potentially neurotoxic at higher doses, that the type of damage is not qualitatively different from that induced by CDDP and that it is dose-dependent. This model, which induces clear-cut pathological changes without severe general side effects, can be effectively used to further study the mechanism by which the neurotoxic effects of CBDCA, alone or in combination with other neurotoxic agents, may arise.
